Showing results (221-230 of 237) with videos related to

Sort By:
Pageof 24
Current Oncology (Toronto, Ont.)|October 25, 2013
Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumoursT Di Valentin, J Biagi, S Bourque, et al.
Nature Medicine|September 15, 2021
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySokratis A Apostolidis, Mihir Kakara, Mark M Painter, et al.
Immunity|August 28, 2021
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccinationMark M Painter, Divij Mathew, Rishi R Goel, et al.
Science Immunology|April 16, 2021
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccinationRishi R Goel, Sokratis A Apostolidis, Mark M Painter, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Divergent ontogeny of Tissue Resident Memory and Tissue Resident Exhausted CD8+ T cells underlies distinct functional potentialSimone L Park, Mark M Painter, Sasikanth Manne, et al.
Current Oncology (Toronto, Ont.)|June 7, 2012
Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancersT Di Valentin, Y Alam, A Ali Alsharm, et al.
Nature Immunology|December 30, 2025
Tissue-resident exhausted and memory CD8+ T cells have distinct ontogeny, function and role in diseaseSimone L Park, Mark M Painter, Sasikanth Manne, et al.
Cell|May 6, 2022
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccineRishi R Goel, Mark M Painter, Kendall A Lundgreen, et al.
Biorxiv : the Preprint Server for Biology|March 2, 2022
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccineRishi R Goel, Mark M Painter, Kendall A Lundgreen, et al.
Nature Communications|June 8, 2021
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosusSarfaraz A Hasni, Sarthak Gupta, Michael Davis, et al.
Pageof 24